Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 15 2022 - 4:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2022
Commission File Number: 001-38245
Akso Health Group
(Exact name of registrant as specified in its charter)
Room 515,
Floor 5, Jia No. 92-4 to 24 Jianguo Road
Chaoyang District, Beijing 100020
People's Republic of China
Tel: +86 10 5370 9902
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note : Regulation
S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual
report to security holders.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation
S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document
that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of
the home country exchange on which the registrant’s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing
a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Resignation and Appointment of Independent
Directors
Mr. Stephen Markscheid,
an independent director of Akso Health Group (the “Company”), chairman of the compensation committee of the board of
directors of the Company (the “Board”), member of the audit committee and nominating & corporate governance
committee of the Board, notified the Company of his resignation as a director for personal reasons, effective April 11, 2022. Mr. Markscheid’s
resignation from the Board was not a result of any disagreement with the Company on any matter related to the operations, policies, or
practices of the Company.
Effective on April 11,
2022, the board of directors of the Company appointed Mr. Stephen P. Brown as an independent director of the Board, chairman of the
compensation committee of the Board, member of the audit committee and nominating & corporate governance committee of the Board
to fill the vacancies created by Mr. Markscheid’s resignation. The biographical information of Mr. Brown is set forth
below.
Mr. Brown, has served
as the chief financial officer of SolarMax Technology, Inc. since May 2017. From 2013 until April 2017, he was chief financial
officer of STAAR Surgical Company. Mr. Brown was vice president, global finance of Bausch & Lomb from 2008 until 2013 and
chief financial officer of Hoya Surgical Optics from 2007 to 2008. He served in various capacities over a 13-year period with Johnson &
Johnson including chief financial officer of the Advanced Sterilization Products division. Mr. Brown holds a Master of Business Administration
degree from University of California, Los Angeles Anderson School of Management, and earned a Bachelor’s degree from California
State University, Fullerton.
Mr. Brown does not have
a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company
during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Brown also entered
into a director offer letter (the “Offer Letter”) with the Company which establishes other terms and conditions governing
his service to the Company. The Offer Letter is qualified in its entirety by reference to the complete text of the Offer Letter, which
is filed hereto as Exhibit 99.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Akso Health Group |
|
|
|
|
|
By: |
/s/ Zhang Rui (Kerrie) |
|
|
Name: Zhang Rui (Kerrie) |
|
|
Title: Chief Financial Officer |
|
|
|
Date: April 15, 2022 |
|
|
Xiaobia Maimai (NASDAQ:HX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xiaobia Maimai (NASDAQ:HX)
Historical Stock Chart
From Sep 2023 to Sep 2024